The Business Columns section of Indonesia Investments provides in-depth columns that exhibit an analysis regarding subjects that are both important for understanding the Indonesian business climate and have high news value in the current state of Indonesia's economy. As a whole these columns should provide the reader a thorough and detailed picture of multiple Indonesian business sectors and be a source of ideas or inspiration to invest - or not to invest - in specific sectors of the Indonesian economy.
Elisa Sinaga, Chairman of the Indonesian Ceramic Industry Association (ASAKI), still expects domestic demand for ceramic products to remain bleak as there are no signs of improvement originating from Indonesia's property sector (compared to last year). However, Indonesia's ceramic exports are expected to rise in 2017.
Huibert Vigeveno, EVP Global Commercial at Royal Dutch Shell Plc, recently visited Indonesia and shared information about Shell's views on the Indonesian oil and gas market. Shell, a British–Dutch multinational oil and gas company, has a long - more than 100 years - history in Indonesia and seems committed to stay in Southeast Asia's largest economy for a long time as Vigeveno names Indonesia an important market for Shell.
Unilever Indonesia, one of the largest consumer goods producers in Indonesia, will continue to focus on the strengthening of its production lines. The company plans to invest up to USD $500 million over the next five years. Sancoyo Antarikso, External Relations Director & Corporate Secretary at Unilever Indonesia, said the funds will be used to expand production capacity of the company's nine factories across Indonesia.
Exports of pharmaceutical products from Indonesia have declined due to increasing competition from China on the international market. Chinese pharmaceutical companies dominate export markets supported by China's low production cost environment and the availability of raw materials at home. However, despite this situation, the Indonesian Pharmacy Association (GP Farmasi Indonesia) remains optimistic that Indonesia's pharmaceutical exports can climb in 2017.
The views expressed in these business columns are the views of the authors or the interviewed persons only and therefore do not necessarily reflect the views of Indonesia Investments. The authors are free to ventilate their opinions about the Indonesian business climate. Facts presented in these columns are the result of the author's own research or indicated sources, read disclaimer.
